Christiana Stamoulis

Track

Insider profile

Currently holds positions in Incyte Corp and Hologic Inc

Positions

Position Company Period
Chief Financial Officer, Executive Vice President Incyte Corp Feb. 11, 2019 -
Independent Director Hologic Inc Nov. 1, 2011 -
President, Chief Financial Officer Cogent Biosciences, Inc. Feb. 1, 2018 - Jan. 31, 2019
Chief Financial Officer, Head - Corporate Development Cogent Biosciences, Inc. Jan. 12, 2015 - Feb. 1, 2018
Senior Vice President - Corporate Strategy and Business Development Vertex Pharmaceuticals Incorporated Oct. 1, 2009 - Jan. 1, 2013
Christiana Stamoulis's trades of Incyte Corp's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
US Incyte Corp (INCY)
Transaction date
Proposed sale
Price
391.09
Quantity 96,611
Value US$4,102,015
US Incyte Corp (INCY)
Transaction date
Proposed sale
Price
459.02
Quantity 8,208
Value US$1,173,363
US Incyte Corp (INCY)
Transaction date
Proposed sale
Price
102.70
Quantity 23,330
Value US$969,719
US Incyte Corp (INCY)
Transaction date
Proposed sale
Price
94.00
Quantity 14,986
Value US$1,408,684
US Hologic Inc (HOLX)
Transaction date
Planned sale
Price
73.07
Quantity 7,402 -13.5%
Value US$540,864
US Hologic Inc (HOLX)
Transaction date
Proposed sale
Price
73.07
Quantity 7,402
Value US$540,864
US Hologic Inc (HOLX)
Transaction date
Planned sale
Price
79.50
Quantity 9,039 -16.6%
Value US$718,600
US Hologic Inc (HOLX)
Transaction date
Proposed sale
Price
79.50
Quantity 9,039
Value US$718,600
US Hologic Inc (HOLX)
Transaction date
Planned sale
Price
74.00
Quantity 11,146 -22.1%
Value US$824,804
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-12-15 2025-12-15
US Incyte Corp (INCY)
PrS Proposed sale
96,611
391.09
US$4,102,015 		96,611 391.09 US$4,102,015
2025-11-12 2025-11-12
US Incyte Corp (INCY)
PrS Proposed sale
8,208
459.02
US$1,173,363 		8,208 459.02 US$1,173,363
2025-11-03 2025-11-03
US Incyte Corp (INCY)
PrS Proposed sale
23,330
102.70
US$969,719 		23,330 102.70 US$969,719
2025-10-30 2025-10-30
US Incyte Corp (INCY)
PrS Proposed sale
14,986
94.00
US$1,408,684 		14,986 94.00 US$1,408,684
2025-10-22 2025-10-20
US Hologic Inc (HOLX)
PlS Planned sale
7,402 -13.5%
73.07
US$540,864 		7,402 -13.5% 73.07 US$540,864
2025-10-20 2025-10-20
US Hologic Inc (HOLX)
PrS Proposed sale
7,402
73.07
US$540,864 		7,402 73.07 US$540,864
2024-07-19 2024-07-17
US Hologic Inc (HOLX)
PlS Planned sale
9,039 -16.6%
79.50
US$718,600 		9,039 -16.6% 79.50 US$718,600
2024-07-17 2024-07-17
US Hologic Inc (HOLX)
PrS Proposed sale
9,039
79.50
US$718,600 		9,039 79.50 US$718,600
2020-11-06 2020-11-04
US Hologic Inc (HOLX)
PlS Planned sale
11,146 -22.1%
74.00
US$824,804 		11,146 -22.1% 74.00 US$824,804